Teenager who received Elevidys, Sarepta’s Duchenne gene therapy, dies
Elevidys was approved after intense debate at the FDA, as officials and reviewers disagreed over how strong the evidence was and whether it warranted making the drug available for patients facing a fatal disease with few other options.
Investor's Business Daily on MSN21h
Sarepta's 27% Sell-Off Is 'Overblown,' 'Overdone' And 'Overly Bearish.' Here's Why It Happened.Sarepta stock crashed Tuesday after a patient who received its approved gene therapy, Elevidys, died due to acute liver failure.
Cambridge-based Sarepta Therapeutics said Tuesday that a patient died while taking its closely watched gene therapy for ...
StockStory.org on MSN1d
Why Sarepta Therapeutics (SRPT) Shares Are Sliding TodayShares of biotech company Sarepta Therapeutics (NASDAQ:SRPT) fell 24.9% in the pre-market session after the company reported ...
Data from the EMBARK trial of delandistrogene moxeparvovec in patients with Duchenne muscular dystrophy (DMD) show that ...
Sarepta will update Elevidys’ label after a patient died following treatment; the FDA issues flu vaccine recommendations ...
Cambridge, Mass.-based Sarepta Therapeutics reported the first known death from its Duchenne muscular dystrophy gene therapy ...
1don MSN
More than 800 people have been treated with Elevidys, the only approved treatment for Duchenne muscular dystrophy, the company said.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback